Showing results (91-100 of 114) with videos related to
Sort By:
Pageof 12
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 24, 2012
VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO SurveyMario Cozzolino, Diego Brancaccio, Giuseppe Cannella, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 17, 2009
Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patientsLuigi Francesco Morrone, Sandro Mazzaferro, Domenico Russo, et al.Journal of Medical Economics|June 19, 2012
Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO studyDaniela Paola Roggeri, Sandro Mazzaferro, Diego Brancaccio, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 24, 2016
Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?Vincent M Brandenburg, Pieter Evenepoel, Jürgen Floege, et al.Journal of Personalized Medicine|March 27, 2026
Renal Involvement in Cancer Patients Undergoing Oncology Therapies: Implications for Personalized Treatment StrategiesSilvia Lai, Alessandra Punzo, Adolfo M Perrotta, et al.Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|March 28, 2018
[Day of Prevention of Renal Diseases in Amatrice, Italy]Silvia Lai, Walter Valentini, Luca Poli, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 12, 2023
Recommended calcium intake in adults and children with chronic kidney disease-a European consensus statementPieter Evenepoel, Hanne Skou Jørgensen, Jordi Bover, et al.Current Vascular Pharmacology|September 22, 2020
Cardiovascular Risk and Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients on Therapy With Tolvaptan: A Pilot StudySilvia Lai, Marco Mangiulli, Adolfo M Perrotta, et al.Clinical Kidney Journal|March 3, 2023
Management of fracture risk in CKD-traditional and novel approachesMathias Haarhaus, Louise Aaltonen, Daniel Cejka, et al.Biomedicines|June 26, 2026
Cardiovascular and Renal Risk Stratification in Patients Referred to an Onconephrology Clinic and Undergoing Different Oncology Therapies: A Real-World StudySilvia Lai, Adolfo Marco Perrotta, Giovanni Pintus, et al.Pageof 12